FBT Biotech ETF Tops Category Returns, Outpaces IBB
FBT biotech ETF is up 20.35% YTD and 53.20% over one year, beating category averages and IBB. Its concentrated equal-weight 30-stock portfolio carries a 0.55% expense ratio and $2.9B AUM.
Corcept Therapeutics
CompanyAlso known as: Corcept Therapeutics Inc.
Related News
Pharmaceutical Sector Q4 Earnings Mixed; XPH ETF Posts 29% One-Year Return
Q4 earnings were mixed across 17 tracked pharmaceutical companies. Elanco and ANI Pharmaceuticals beat revenue estimates, while Corcept and Amphastar missed. The XPH pharma ETF posted a 29% one-year return but significantly lagged the S&P 500 over five and ten years.
Court ruling clears path for Teva generic to challenge Corcept's Korlym
A federal appeals court affirmed a ruling finding no infringement of two Korlym-related patents by Teva's proposed generic. The decision removes a major legal barrier for generic competition.
Corcept executives sued over drug approval remarks and insider stock sales
Corcept Therapeutics executives and directors were sued over alleged misstatements about a drug candidate’s approval prospects. The suit says insider stock sales totaled $97 million while the stock price was artificially inflated.
FDA Rejects Corcept's Relacorilant Application; Securities Lawsuits Follow
Corcept Therapeutics received an FDA Complete Response Letter denying approval of relacorilant for hypertension secondary to hypercortisolism, triggering a 44.76% stock decline and multiple securities class actions.
Related Clinical Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07276373 |
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies |
RECRUITING | PHASE1/PHASE2 |
| NCT07259317 |
Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma |
RECRUITING | PHASE2 |
| NCT06947304 |
Evaluation of Miricorilant on Liver Fat in Patients With MASLD |
ACTIVE_NOT_RECRUITING | PHASE1 |
| NCT06906341 |
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers |
RECRUITING | PHASE2 |
| NCT05407324 |
Dazucorilant in Patients With Amyotrophic Lateral Sclerosis |
RECRUITING | PHASE2 |
| NCT03604198 |
Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome |
ACTIVE_NOT_RECRUITING | PHASE2 |